“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:
Nanoparticle Drug Delivery Market Overview
Nanoparticle Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 190
Majority of Nanoparticle Drug in Preclinical Phase: 70
Marketed Nanoparticle Drugs: 12
Suspended & Discontinued Drug Profiles
Cancer nanomedicine market & pipeline insight 2015KuicK Research
“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at alternative delivery for mRNA vaccines.
Helen McCarthy, pHion Therapeutics
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at overcoming the challenges of scaling up a complex medicine.
Graham Worrall and Emily Port, CPI
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
Cancer nanomedicine market & pipeline insight 2015KuicK Research
“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at alternative delivery for mRNA vaccines.
Helen McCarthy, pHion Therapeutics
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at overcoming the challenges of scaling up a complex medicine.
Graham Worrall and Emily Port, CPI
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at whether complex medicines raise different challenges from a safety perspective.
Richard Knight (Apconix)
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...KuicK Research
“Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” Report Highlights:
Introduction to Cancer Tyrosine Kinase Inhibitors
Signaling Pathway of Receptor Tyrosine Kinase
Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
Global Tyrosine Kinase Inhibitors Market Overview
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs
Poster on the IUPHAR/MMV Guide to Malaria Pharmacology presented by Dr. Jane F. Armstrong at the EMBL BioMalPar XV: Pathology of the Malaria Parasite, EMBL Heidelberg, Germany May 2019
Alternative animal model for compound characterizationWenlan Hu
To pick a model is not easy thing to do, especially when nutraceutical market needs have to be met. Such market requires low budget, fast turn-around rate, and high-quality data at the same time. Traditional models such as mice and cell cultures usually only meet one need at one time. IVB uses C.elegans and zebrafish which lies in the middle of the model spectrum in terms of the three needs to perfectly accommodate all of them at the same time.
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at cellular internalisation and trafficking of complex medicines.
Dr Jamie Szczerkowski, Medicines Discovery Catapult
Good Model Organism for Anti Aging TestingWenlan Hu
Drug testing is taking more attention than ever before in a fast growing market for longevity compounds. In order to succeed in a competitive market and develop a pipeline method for quick drug development, we need to understand and choose the most suitable model organism for aging studies. The following content is intended to provide information on how to choose the best model for anti-aging drug testing.
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Cancer immunomodulators market & pipeline insight 2020KuicK Research
"Cancer Immunomodulators Market & Pipeline Insight 2020" Report Highlights:
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
Marketed Cancer Immunomodulators: 47
Cancer Immunomodulators Drug Patent Analysis
11 years old presentation submitted as Project work: Golden Mantra to Perform Worldwide Patent Searches
Patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, usually 20 years from the filing date. A patent is, in effect, a limited property right that the government offers to inventors in exchange for their agreement to share the details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
In order to obtain a patent, an applicant must provide a written description of his or her invention in sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention.
Updated poster following beta v3 release. In preparation for Pharmacology Futures, Edinburgh Immunology Symposium and Word Congress of Pharmacology (Kyoto)
Poster presented at the Elixir All-Hands Meeting in Lisbon, June 2019. Gives a broad summary of Guide to Pharmacology activities in the last year. Emphasising new tools and our extension into malaria pharmacology.
Cancer nanomedicine market & pipeline insight 2015KuicK Research
“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at whether complex medicines raise different challenges from a safety perspective.
Richard Knight (Apconix)
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...KuicK Research
“Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” Report Highlights:
Introduction to Cancer Tyrosine Kinase Inhibitors
Signaling Pathway of Receptor Tyrosine Kinase
Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
Global Tyrosine Kinase Inhibitors Market Overview
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs
Poster on the IUPHAR/MMV Guide to Malaria Pharmacology presented by Dr. Jane F. Armstrong at the EMBL BioMalPar XV: Pathology of the Malaria Parasite, EMBL Heidelberg, Germany May 2019
Alternative animal model for compound characterizationWenlan Hu
To pick a model is not easy thing to do, especially when nutraceutical market needs have to be met. Such market requires low budget, fast turn-around rate, and high-quality data at the same time. Traditional models such as mice and cell cultures usually only meet one need at one time. IVB uses C.elegans and zebrafish which lies in the middle of the model spectrum in terms of the three needs to perfectly accommodate all of them at the same time.
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at cellular internalisation and trafficking of complex medicines.
Dr Jamie Szczerkowski, Medicines Discovery Catapult
Good Model Organism for Anti Aging TestingWenlan Hu
Drug testing is taking more attention than ever before in a fast growing market for longevity compounds. In order to succeed in a competitive market and develop a pipeline method for quick drug development, we need to understand and choose the most suitable model organism for aging studies. The following content is intended to provide information on how to choose the best model for anti-aging drug testing.
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Cancer immunomodulators market & pipeline insight 2020KuicK Research
"Cancer Immunomodulators Market & Pipeline Insight 2020" Report Highlights:
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
Marketed Cancer Immunomodulators: 47
Cancer Immunomodulators Drug Patent Analysis
11 years old presentation submitted as Project work: Golden Mantra to Perform Worldwide Patent Searches
Patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, usually 20 years from the filing date. A patent is, in effect, a limited property right that the government offers to inventors in exchange for their agreement to share the details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
In order to obtain a patent, an applicant must provide a written description of his or her invention in sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention.
Updated poster following beta v3 release. In preparation for Pharmacology Futures, Edinburgh Immunology Symposium and Word Congress of Pharmacology (Kyoto)
Poster presented at the Elixir All-Hands Meeting in Lisbon, June 2019. Gives a broad summary of Guide to Pharmacology activities in the last year. Emphasising new tools and our extension into malaria pharmacology.
Cancer nanomedicine market & pipeline insight 2015KuicK Research
“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
These slides use concepts from my (Jeff Funk) course entitled analyzing hi-tech opportunities to show how nanotechnology for drug deliver is becoming economically feasible.
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
A General Overview of Nano Medicine-Efficacy in Therapeutic Science and Curre...Berklin
Nanotechnology’s introduction has dramatically improved a number of scientific fields, one of which is medicinal research. Nanomedicine is aimed to offer healthcare medications and chemicals a new dimension. The small size of nanoparticles, permits them to circulate in the body without interrupting oxygenation and escape filtration by both the renal and gastrointestinal networks. These are the few properties that distinguish them apart from traditional therapeutic procedures. The increased permeability and durability effect result in successful penetration inside the tumor tissues, providing cancer treatment a new lease on life. Efficient transportation pathways, on the other hand, produce genotoxicity and mutagenicity by interacting with genes that are essential for smooth functioning. As the specific interactions of nanomedicines with biological systems are still unknown, comprehending nanomedicines' toxicological effects is tough. The lack of regulatory direction in this field remains a research gap that we would want to examine in this study.
Global cancer cdk inhibitors market & clinical pipeline outlook 2022KuicK Research
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Cd antigen cancer therapy market outlook & clinical trials insight 2023KuicK Research
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
• Market Opportunity Assessment: More than US$ 60 Billion by 2023
• Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
• Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
• Dosage & Price Analysis on Key Drugs
• Mechanism of CD Antigen Cancer Therapeutics
• Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
• Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
Global orphan drug market designation status clinical pipeline trials insigh...KuicK Research
“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:
• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines
“US Shale Gas Industry Analysis” Report Highlight:
* US Shale Gas Industry Overview
* Shale Gas Exploration, Technical and Technology Aspects
* US Shale Gas Reserve Analysis: Technical & Recoverable Reserves
* Investments in Shale Gas Exploration & Production
* US Shale Gas Sector Dynamics
* Shale Boom to Drive LNG Export Projects
Download Us biosimilars market opportunity & clinical pipeline analysisKuicK Research
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
* US Biosimilars Market Introduction
* US Biosimilars Regulatory Scenario
* Unique Features of US Biosimilars Market
* Impact of Biosimilars in US Market
* Impact of Reimbursement Policies on US Biosimilars Market
* Zarxio: First Approved Biosimilar in US
* US Biosimilar Clinical Pipeline By Company, Indication & Phase
* US Biosimilar Clinical Pipeline: 104 Biosimilars
* Marketed Biosimilars: 1 Biosimilar*
Download Uae nuclear power sector opportunity analysisKuicK Research
“UAE Nuclear Power Sector Opportunity Analysis” Report Highlight:
* UAE Energy Policy beyond Oil & Gas
* UAE Nuclear Power Sector Overview
* UAE Nuclear Power Sector Dynamics
* Nuclear Power Sector Management & Regulatory Framework
* Nuclear Power Sector Regulations
* Details of Nuclear Power Plants in UAE
* UAE Nuclear Power Sector Future Outlook
Download Turkey wind power sector outlook 2017KuicK Research
“Turkey Wind Power Sector Outlook 2017” gives comprehensive insight on following aspect related to wind power sector development in Turkey:
* Wind Power Sector Overview
* Wind installed Capacity & Generation
* Operating Wind Farms by Province & Company
* Onshore & Offshore Wind Potential
* Emerging Trends
* Policy Framework
* Competitive Landscape
Download South korea wind power sector analysis 2013KuicK Research
“South Korea Wind Power Sector Analysis 2013” research report discusses following aspect related to emerging wind power sector in South Korea:
* Current Sector Trends
* Onshore & Offshore Wind Potential
* Wind Power Sector Indicators
* Operating Wind Farms
* Future Outlook & Sector Emerging Trends
* Regulatory & Policy Framework
* Competitive Landscape
Download Saudi arabia airport privatization opportunity outlook 2022KuicK Research
“Saudi Arabia Airport Privatization Opportunity Outlook 2022” report highlights:
Saudi Arabia Aviation Industry Overview
Privatization in Saudi Arabia
Investment and Expansion Opportunities for International Investors
Civil Aviation Laws and Policies Framework
Ongoing Privatization Projects
Privatization Build - Operateandndash;Transfer (BOT) Business Model
Download Non hodgkin lymphoma therapeutics market & pipeline insightKuicK Research
“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:
Global Non Hodgkin Lymphoma Market Overview
Mechanism of Non Hodgkin Lymphoma Therapeutics
Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
Majority of the Drugs are in Phase-I: 54 Drugs
Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
Patent Analysis by Country, Year & Compositions
Download Japan generics drug market outlook 2020KuicK Research
“Japan Generics Drug Market Outlook 2020” Report Highlights:
Introduction to Japanese Generic Drug Market
Attractiveness of Japanese Generic Market
Super Generics in Japan
Japan Healthcare System & Generic Drugs
Different Parameters for Generic & Branded Drugs
Comparison of Generic Drugs in US & Japan
Japan Generics Drug Market Analysis
Japan Generics Drug Market Future Prospects
Download India urban and industrial waste to energy marketKuicK Research
The Urban and Industrial waste based power projects have been witnessing upward trend in recent years driven by increasing investments from private sector and ongoing government initiatives to promote generation of power from urban and industrial waste. The overall installed capacity of grid connected waste power projects surpassed 70 MW by end of 2011 as compare to more than 90 MW of off grid waste base power projects.
Considering the huge potential to convert waste to energy in India, the Ministry of Environment and Forests had formulated the Municipal Solid Wastes Management and Handling Rules in 2000. Waste to Energy is understood as a renewable technology, and comes under the overall guidance and facilitation of the Ministry of Non Renewable Energy of India, which has announce finacila incentives and assistance programme in.
Download India nuclear power sector generation and investment opportunity out...KuicK Research
“India Nuclear Power Sector Generation and Investment Opportunity Outlook 2032” report highlights:
India Nuclear Power Sector Overview
India Nuclear Power Sector Indicators
India Existing and upcoming Nuclear Power Plants Overview
Indian Nuclear Power Regulatory and Policy Framework
India Nuclear Power Plants Infrastructure
India Nuclear Fuel Supply Scenario
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Download Nanoparticle drug delivery market & clinical pipeline insight
1. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 1
Drug delivery technologies currently occupy a significant position in the pharmaceutical
industry. It has become so important that the mode of delivery of drugs has come to define
the efficiency and marketability of those drugs. The pharmaceutical industry is witnessing a
shift in the focus of the stakeholders towards newer systems of drug delivery in order to
achieve efficient and safe transportation of novel products and formulations. There have
been many products which have been derived from new delivery systems and are currently
attracting the attention of different companies. It has been recognized that the introduction
of a new drug delivery system would bring along a potential chance for an existing drug
candidate molecule.
The field of nanotechnology is considered to be an exciting area which offers the potential for
developing drug delivery systems using nanoparticles, with dimension range of 1-100 nm.
These nanoparticles tend to have the ability to deliver an adequate range of molecules to
different areas of the body. Additionally, these nanoparticles also posses the capability to
deliver the molecules for a comparatively longer duration of time as compared to other
routes. The major objectives of a drug delivery system based on nanoparticles, are size of
particles, surface properties and discharge of drugs or the active ingredients in order to
attain the maximum level of efficiency.
The combination of nanotechnology along with medicine has resulted in potential concepts
and ideas for the pharma industry which is set to introduce momentous innovations in the
fight against different diseases. The two concepts of therapeutic nanocarriers – liposomes and
albumin nanoparticles are gaining prominence rapidly and would soon become well-
established in the market across the globe. The need of the hour currently is to obtain a
deeper understanding of the biodistribution of nanoparticles, which is influenced mainly by
their ability to negotiate biological barriers.
Additionally, a significant growth of this field would mostly depend on the strong
establishment of a toxicology database which would support the safety determinations and
risk assessments. This database could possibly include toxicity as a function of material, size,
shape, cell type or animal, duration of exposure and the methods which are used to assay
toxicity. Also, there needs to be a mechanism wherein the scaling up of production levels of
drug particles is enabled.
2. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 2
Finally, this database should also consider protocols relating to storage and handling. The use
of such a compact database would help the pharma industry to translate biomedical
nanotechnology from the laboratory to the general public at ease.
“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report
Highlights:
• Nanoparticle Drug Delivery Market Overview
• Nanoparticle Drug Delivery Mechanism
• Clinical Pipeline by Phase & Target Indications
• Drug Profiles in Report: 190
• Majority of Nanoparticle Drug in Preclinical Phase: 70
• Marketed Nanoparticle Drugs: 12
• Suspended & Discontinued Drug Profiles
For Report Sample Contact: neeraj@kuickresearch.com
3. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 3
Table of Contents
1. Introduction to Nanoparticle Technology for Drug Delivery
2. Nanoparticle Drug Delivery Mechanism
2.1 Protein Based Delivery Systems
2.2 Natural Polymers & Derivates
2.3 Polymeric Carriers
2.4 Dendrimers
2.5 Fullerene
2.6 Carbon Nanotubes
3. Application of Nanotechnology for Drug Delivery
4. Nanoparticle Drug Delivery Market Overview
4.1 Market Overview
4.2 Clinical Insight
5. Nanoparticle Drug Delivery Market Dynamics
5.1 Drivers
5.2 Challenges
5.3 Future Outlook
6. Nanoparticle Drug Delivery Clinical Pipeline by Phase, Country & Indication
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
4. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 4
6.5 Phase II
6.6 Phase II/III
6.7 Phase III
7. Marketed Nanoparticle Drug
8. Suspended & Discontinued Nanoparticle Drug Profiles
8.1 No Development Reported
8.2 Discontinued
8.3 Suspended
9. Competitive Landscape
9.1 Abraxis BioScience
9.2 Access Pharmaceuticals
9.3 Alnylam Pharmaceuticals
9.4 Arrowhead Research
9.5 BIND Biosciences
9.6 iCeutica
9.7 NanoCarrier
9.8 Nippon Kayaku
9.9 Nanobiotix
9.10 Samyang
5. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 5
List of Figures
Figure 1-1: Nanoparticle Technology for Drug Delivery
Figure 1-2: Nanoparticle Class
Figure 2-1: Nanoparticle Drug Delivery System
Figure 4-1: Nanoparticle Drug Delivery Market (US$ Billion), 2013-2020
Figure 4-2: Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-3: Number Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-4: No Development in Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-5: Number of No Development in Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 4-6: Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-7: Number of Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 4-8: Suspended Nanoparticle Drugs in Clinical Pipeline by Phase (%)
Figure 4-9: Number of Suspended Nanoparticle Drugs in Clinical Pipeline by Phase
Figure 9-1: Arrowhead Research Corporation Clinical Pipeline
Figure 9-2: NanoCarrier Clinical Pipeline
For Report Sample Contact: neeraj@kuickresearch.com